Emerging EMG Growth Natus Sensory Newborn Care operates within a broader Natus Medical portfolio that includes advanced neurodiagnostic and sensory systems, with recent EMG software updates signaling continued product refresh. This presents cross-sell and upsell opportunities to customers already invested in Natus hardware and software ecosystems.

Board & Leadership Signals New board member appointment in 2026 indicates potential strategic shifts and governance focus, creating openings for executive-level introductions and alignment on expansion into new markets or product lines, particularly in neurodiagnostics and sensory solutions.

Acquisition Momentum The group’s recent acquisition activity, including Holberg EEG, suggests a strategy to augment AI-enabled neurodiagnostic capabilities. This creates opportunities to position integrated neurodiagnostic workflows and analytics within hospital networks seeking comprehensive solution footprints.

Global Sales Acceleration Key hires in 2025 for leadership in global hearing and balance, plus a Chief Commercial Officer appointment, indicate a push to scale international sales, marketing, and service. Target hospitals and clinics with expanding newborn and neurodiagnostic programs to capitalize on this growth trajectory.

Clinical Value Proposition The emphasis on early detection and treatment to reduce costs and hospital readmissions aligns with payer and hospital care pathways. Position offerings as end-to-end newborn assessment and treatment solutions that integrate with existing ICU and NICU workflows to drive outcome improvements and cost containment.